Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD036 in Obstructive Sleep Apnea
NCT04445688Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine + oxybutynin in obstructive sleep apnea (OSA), sponsored by Apnimed, Inc.. Started Jul 2020; status: completed.
02
Drugs
atomoxetine + oxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04445688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445688.